https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833340/
Early treatment of symptomatic COVID-19 patients with antihistamines and azithromycin, and administration of antihistamines in asymptomatic and high risk patients, close contacts and relatives, had excellent outcomes in our population reducing fatality rate, hospital admissions and ICU admissions in this elderly population, regardless of patient's age and risk factors.
This safe and inexpensive treatment protocol could have a crucial impact on morbidity and mortality rates of patients with COVID-19 and ease the burden of these patients on hospitals. Treatment should be started at the Primary Health Care level, as early as possible when the first symptoms appear. Antihistamines and azithromycin are drugs with extensive experience of use, good safety profile, good tolerance, low cost and wide availability, so this combined treatment regimen may respond to the global therapeutic needs for COVID-19 for all age groups. Clinical trials are necessary to determine its efficacy. As there are no commercial interests, they should be promoted by national health systems as a social responsibility.
If you’re experiencing a runny nose and itchy eyes, chances are you’ve just got a cold. These tend to be localized to the head, giving you some nasal backup, and maybe even a nasal headache if the pressure builds up. This could be alleviated with over the counter antihistamines like diphenhydramine (Benadryl) or loratadine (Claritin), and you are probably not seriously ill. Unless you have a preexisting condition like asthma, you will likely not experience shortness of breath due to allergies.
